The last week was not good for AstraZeneca profits derived through Seroquel as courts on both sides of the Atlantic said patents giving market exclusivity to the company's top-selling antipsychotic drug were invalid.
AstraZeneca is based in the United Kingdom, but has a big facilities in Wilmington and Newark, Del.
A federal judge in Washington on Friday dismissed a lawsuit filed by AstraZeneca against the U.S. Food and Drug Administration, in which the company sought to overturn the FDA's approval of a generic form of the drug. That means the generic version can be sold immediately.
Meanwhile, the High Court in the UK said the Seroquel long-release tablet did not have patent protection in that country. Teva Pharmaceuticals was among the generic companies fighting AstraZeneca in court in that dispute.